PDSB PDS Biotech: Company Book Value

Official company branding of PDS Biotechnology Corp (PDSB)

The daily price chart for PDS Biotechnology (PDSB) reflects the dynamics of a biotech firm developing advanced vaccines to stimulate T-lymphocytes in the fight against viral tumors. The current value is -0.01. Market capitalization relies on future sales of the PDS0101 drug for HPV-related diseases, while the high cost of FDA certification and patents for the Versamune system provide PDS Biotechnology (PDSB) with a sustainable competitive advantage.

PDS Biotech (PDSB) - Company Book Value from 07/04/2022 to 10/27/2026

Comprehensive metric breakdowns and analytics for PDS Biotechnology Corp (PDSB)

- price and consensus price forecast:
Market Chart PDS Biotechnology|PDSB - Analyst Consensus Forecast
- market capitalization data:
Market Value PDS Biotech|PDSB - Total Company Value
- book capitalization data:
Net Asset Value per Share PDS Biotechnology|PDSB - Company Book Value|Capitalization to Book Value Ratio pdsbiotech.com|PDSB - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio PDS Biotechnology|PDSB - Long-Term Debt to Equity|Current Liabilities to Capital PDS Biotechnology|PDSB - Company Debts|Debt to Book Capitalization Ratio PDS Biotech
Initial company analysis:PDS Biotechnology Corporation - PDSB
Flagship merchandise of PDS Biotech

Book value measures the net value of a company's own property, allowing an investor to strip away market speculation and assess the actual volume of assets. By analyzing the company's capital history on the balance sheet, one can diagnose the financial stability of PDS Biotechnology during the development of innovative vaccines that activate T-cells to combat viral tumors and destroy cancer cells.

Key competitors

IBRX - Book Valuation of Business|Immunocore Holdings plc (IMCR) - Book Capitalization|JANX (januxrx.com) - Company Book Value|Company Book Value RCUS (Arcus Biosciences)|Total Stockholders' Equity ZYME|Company Book Value Tango Pharma TNGX|Accounting Capitalization Iovance Corp (IOVA)|Immatics N.V. - Book Capitalization|xencor.com - Company Net Assets|CMPX (Compass Therapeutics, Inc.) - Company Book Value|REPL: Total Stockholders' Equity|Lyell Immunopharma Inc (LYEL) - Company Book Value|IPHA (Innate Pharma S.A) - Company Book Value|Company Book Value PYXS (Pyxis Oncology Inc.)|Total Stockholders' Equity Compugen Limited|IOBT: Book Capitalization|Book Value of Business Sutro Biopharma Inc. STRO|INKT: Company Net Assets|HOWL - Total Stockholders' Equity|Company Net Assets Immix (IMMX)|ALXO - Accounting Value of Company|Cue Biopharma - Book Capitalization|SONN (Sonnet BioTherapeutics Holdings) - Book Valuation of Business|Company Book Value MAIA|Company Net Assets LIMN|Company Book Value LVTX (LAVA Therapeutics N.V.)|Company Net Assets nextcure.com NXTC|Company Net Assets LPTX (Leap Therapeutics)|Intensity Therapeutics Inc - Book Capitalization|Sensei Bio (SNSE) - Company Book Value|TOVX: Accounting Capitalization|Company Book Value GRTS|Total Stockholders' Equity kinetabio.com|NexImmune - Company Net Assets|Book Value of Business Turnstone Biologics Corporation (TSBX)|Company Net Assets Vaccinex, Inc|Total Net Assets Harpoon Therapeutics Corp (HARP)